Table 2 Demographic data and clinical characteristics between two groups.

From: Cerebral abnormalities in HIV-infected individuals with neurocognitive impairment revealed by fMRI

 

No. (%), mean ± SD or median (IQR)

HIV-NCI (n = 33)

HIV-control (n = 33)

P-value

Average age (year)

61.16 ± 6.88

59.41 ± 5.41

0.25a

Gender (male, %)

32 (97.0)

30 (90.9)

0.29b

Years of education (n[%])

0.41b

 Primary school and below

1 (3.0)

3 (9)

 Junior school

20 (60.6)

17 (51.5)

 Senior school

10 (30.3)

8 (24.2)

 Undergraduate and above

2 (6.0)

5 (15.1)

MMSE score

22.26 ± 2.98

26.55 ± 1.30

0.002a

IHDS score

7.12 ± 1.82

9.27 ± 1.06

0.003a

PSQI score

8.03 ± 3.68

7.40 ± 3.03

0.44a

SAS score

41.88 ± 7.26

40.15 ± 8.06

0.36a

HIV-infected related variables

 Time since HIV diagnosis (years)

5.58 (3.42–7.75)

5.43 (3.39–7.93)

0.83c

 Duration of ART (years)

4.89 (3.16–7.34)

5.29 (3.09–7.41)

0.94c

 AIDS (v.s. HIV, n[%])

13 (39.4)

10 (33.3)

0.47b

 Nadir CD4 count, cells/μL

160 (72–279)

156 (57–255)

0.48c

 Current CD4 count, cells/μL

453 (306–640)

432 (333–620)

0.75c

  1. NCI neurocognitive impairment, wNCI without neurocognitive impairment, MMSE minimum mental state examination, IHDS International HIV Dementia Scale, PSQI Pittsburgh Sleep Quality Index, SAS Self-rating Anxiety Scale, ART antiretroviral therapy, AIDS refer to the AIDS stage of HIV infection, SD standard deviation.
  2. aTwo independent-sample test.
  3. bChi-square test.
  4. cWilcoxon rank sum test.